Estrogen Receptors

Suzanne Fuqua, PhD, Moderator

Baylor College of Medicine, Houston, TX

    Predictive Factors II

4026-4038

4039-4055

4056-4064

4065-4073

4074-4097

4098-4105

4106-4117

52.  The impact of micrometastases in the sentinel nodes of patients with invasive breast cancer.   

Hansen NM, Grube BL, Ye C, Turner R, Brennan M, Brenner J, Giuliano AE. John Wayne Cancer Institute, Santa Monica, CA; Saint John's Hospital and Health Center, Santa Monica, CA.

53.  High sensitivity of a molecular assay for breast metastases in sentinel lymph nodes that are difficult to detect by frozen section. 

Blumencranz P, Deck KB, Whitworth PW, McCue P, Reintgen DS, Chagpar AS, Beitsch P, Julian TB, Mamounas M, Saha S, Giuliano A, Simmons R.  Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Weill-Cornell Breast Center, New York, NY.

54.  Increased sentinel lymph node lymphangiogenesis predicts non-sentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. 

Van den Eynden GG, Vandenberghe MK, van Dam P-JH, Colpaert CG, van Dam P, van Marck EA, Vermeulen PB, Dirix LY. (Lab Pathology University of Antwerp/University Hospital Antwerp, Wilrijk; Oncology Center, GH St-Augustinus, Wilrijk, Belgium), Antwerp, Belgium.

11:00

SYSTEMS BIOLOGY AND TARGETING THE HER NETWORK IN THE TREATMENT OF BREAST CANCER

C. Kent Osborne , MD, Co-Moderator

Baylor College of Medicine, Houston, TX

and

Rachel Schiff, PhD, Co-Moderator

Yosef Yarden, PhD

The Weizmann Institute of Science

Rehovat, ISRAEL

Novel strategies for HER-targeted therapy and mechanisms of resistance

C. Kent Osborne, MD

Baylor College of Medicine

Houston, TX

61.  The influence of a very high vegetable-fruit-fiber, low-fat diet on prognosis following treatment for breast cancer: results from the Women's Healthy Eating and Living (WHEL) randomized trial.   

Pierce JP, Natarajan L, Cann BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson R, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML.  Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Kaiser Permanente Northern California, Oakland, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA; University of California, San Diego; University of California, Davis, Davis, CA; M.D. Anderson Cancer Center, The University of Texas, Houston, TX; Center for Health Research, Portland, OR; Roswell Park Cancer Institute, Buffalo, NY; University of Arizona, Tucson, AZ; Arizona Cancer Center, Arizona Prevention Center, University of Arizona, Tucson, AZ; Stanford Prevention Research Center, Stanford University, Stanford, CA.

62.  Outcome prediction for Clinical Stage II and III ER+ breast cancer based on treatment response, pathological stage, tumor grade, Ki67 proliferation index, and estrogen receptor status after neoadjuvant endocrine therapy. 

Ellis MJ, Tao Y, Luo, Evans DB, Bhatnagar, Chaudri-Ross HA, von Kameke, Miller WR, Eiermann W.  Washington University, St. Louis, MO; Novartis Pharma AG, Basel, Switzerland; Edinburgh University, Scotland; Red Cross Women's Hospital, Munich, Germany.

63.  Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197. 

Goldstein L, Ravdin P, Gray R, Yoshizawa C, Childs B, Rowley S, Shak S, Badve S, Baehner FL, Davidson N, Sledge GW, Sparano JA.  Eastern Cooperative Oncology Group, Brookline, MA; MD Anderson Cancer Center, Houston, TX; Genomic Health, Inc., Redwood City, CA; sanofi aventis, Bridgewater, NJ.

64.  Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 trial of postmenopausal women with estrogen receptor-positive breast cancer. 

Viale G, Giobbie-Hurder A.  BIG 1-98 Collaborative Group and International Breast Cancer Study Group (IBCSG), Bern, Switzerland.

65.  Erythropoietin receptor expression in breast cancer and correlation to tamoxifen response. 

Larsson A-M, Jirstrom K, Rydén L, Landberg G, Pahlman S.  Lund University, University Hospital MAS, Malmo, Sweden.

66.  Inflammatory breast cancer pathogenesis is mediated in significant part by translation initiation factor eIF4G amplification and unorthodox protein synthesis. 

Silvera D, Arju R, Darvishian F, Levine PH, Formenti SC, Schneider RJ.  New York University School of Medicine, New York, NY; The George Washington University School of Public Health and Health Services, Washington, DC.

POSTER DISCUSSION SESSION 5 & RECEPTION – Ballroom B

Alexander H.G. Paterson, Moderator

University of Calgary, Calgary, CANADA

5001-5012

5013-5023

5024-5025

5041-5047

5048-5051

5052-5076

5077-5101

5102-5109

5110-5119

Controversies in Adjuvant Endocrine Therapy for Breast Cancer

This symposium will summarize current clinical data on aromatase

inhibitors in the adjuvant setting, including key distinctions based

on differing trial designs. Case-based debates will stimulate discussion

about clinical issues that are still a matter of controversy.

Dinner & Symposium

Sponsored by Physicians' Education Resource

For information, contact:

Kathryn Wallace

214-367-3329

Fax 214-367-3303

kathryn.wallace@pergrouplp.com

Register on line at: www.adjuvantai.cancerconferences.com

Supported by an educational grant from Novartis Pharmaceuticals Corporation